相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV
Alice Fabarius et al.
BLOOD (2011)
CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia
Hideki Makishima et al.
BLOOD (2011)
The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile
Christopher A. Eide et al.
CANCER RESEARCH (2011)
BCR-ABL stimulates mutagenic homologous DNA double-strand break repair via the DNA-end-processing factor CtIP
Daniela Salles et al.
CARCINOGENESIS (2011)
BCR-ABL1 Kinase: Hunting an Elusive Target with New Weapons
Tomasz Skorski
CHEMISTRY & BIOLOGY (2011)
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
Amie S. Corbin et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia
C. Roche-Lestienne et al.
LEUKEMIA (2011)
A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases
V. Grossmann et al.
LEUKEMIA (2011)
Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors
Ronald L. Paquette et al.
CANCER GENETICS (2011)
New Drugs for Chronic Myelogenous Leukemia
Fabio P. S. Santos et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2011)
SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations
Daniel Nowak et al.
BLOOD (2010)
Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia
Theo D. Kim et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Chronic myeloid leukemia: mechanisms of blastic transformation
Danilo Perrotti et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment
C. Haferlach et al.
LEUKEMIA (2010)
TGF-β-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
Kazuhito Naka et al.
NATURE (2010)
Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia
Letizia Foroni et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
The B Cell Mutator AID Promotes B Lymphoid Blast Crisis and Drug Resistance in Chronic Myeloid Leukemia
Lars Klemm et al.
CANCER CELL (2009)
BCR/ABL induces chromosomal instability after genotoxic stress and alters the cell death threshold
J. Dierov et al.
LEUKEMIA (2009)
Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: From molecular redox mechanisms to health implications
Margret S. Rodrigues et al.
ANTIOXIDANTS & REDOX SIGNALING (2008)
Up-regulation of WRN and DNA ligase IIIα in chronic myeloid leukernia:: consequences for the repair of DNA double-strand breaks
Annahita Sallmyr et al.
BLOOD (2008)
RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance
Catherine Roche-Lestienne et al.
BLOOD (2008)
BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations
Tomasz Stoklosa et al.
CANCER RESEARCH (2008)
BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair
Kimberly Cramer et al.
CANCER RESEARCH (2008)
Effects of Dasatinib on Src Kinase Activity and Downstream Intracellular Signaling in Primitive Chronic Myelogenous Leukemia Hematopoietic Cells
Heiko Konig et al.
CANCER RESEARCH (2008)
Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL
Charles G. Mullighan et al.
GENES & DEVELOPMENT (2008)
Cryptic and Partial Deletions of PRDM16 and RUNX1 Without t(1;21)(p36;q22) and/or RUNX1-PRDM16 Fusion in a Case of Progressive Chronic Myeloid Leukemia: A Complex Chromosomal Rearrangement of Underestimated Frequency in Disease Progression?
Laureline Deluche et al.
GENES CHROMOSOMES & CANCER (2008)
BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress
M. Koptyra et al.
LEUKEMIA (2008)
Multiple sub-microscopic genomic lesions are a universal feature of chronic myeloid leukaemia at diagnosis
J. S. Khorashad et al.
LEUKEMIA (2008)
BCR/ABL, DNA damage and DNA repair: Implications for new treatment concepts
Tomasz Skorski
LEUKEMIA & LYMPHOMA (2008)
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
Charles G. Mullighan et al.
NATURE (2008)
Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia
Su-Jiang Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors
Jorge Cortes et al.
BLOOD (2007)
Genomic profile of chronic myelogenous leukemia: Imbalances associated with disease progression
D. Brazma et al.
GENES CHROMOSOMES & CANCER (2007)
Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase
Elias Jabbour et al.
BLOOD (2007)
Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure
Alice Fabarius et al.
HAEMATOLOGICA (2007)
Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells
Xiaoyan Jiang et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells
Heather G. Jorgensen et al.
BLOOD (2007)
Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment
Cornelius Miething et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Primitive, quiescent and difficult to kill - The role of non-proliferating stem cells in chronic myeloid leukemia
David J. Barnes et al.
CELL CYCLE (2006)
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib
Ian J. Griswold et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance
Mateusz Koptyra et al.
BLOOD (2006)
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition
Hans-Guido Wendel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks
Margaret Nieborowska-Skorska et al.
CELL CYCLE (2006)
Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia
RT Williams et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia
DJ Barnes et al.
CANCER RESEARCH (2005)
High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients; correlation with clonal cytogenetic evolution but not response to therapy
SG Willis et al.
BLOOD (2005)
Induction of centrosome and chromosome aberrations by imatinib in vitro
A Fabarius et al.
LEUKEMIA (2005)
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA working party on chronic myeloid leukemia
S Soverini et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment
B Schultheis et al.
BLOOD (2005)
Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center -: A 4.5-year follow-up
T Lahaye et al.
CANCER (2005)
Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia
M Yamamoto et al.
CANCER GENETICS AND CYTOGENETICS (2005)
Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression
U Bacher et al.
CANCER GENETICS AND CYTOGENETICS (2005)
BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks
MO Nowicki et al.
BLOOD (2004)
Clonal evolution in chronic myelogenous leukemia
J Cortes et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2004)
p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation
Y Canitrot et al.
BLOOD (2003)
The kinase inhibitor STI571 reverses the Bcr-Abl induced point mutation frequencies observed in pre-leukemic P190Bcr-Abl transgenic mice
JM Brain et al.
LEUKEMIA RESEARCH (2002)
BCR-ABL-induced adhesion defects are tyrosine kinase-independent
JA Wertheim et al.
BLOOD (2002)
DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis
C Bernstein et al.
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2002)
A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9
AB Dash et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Oncogenic tyrosine kinases and the DNA-damage response
T Skorski
NATURE REVIEWS CANCER (2002)
Cytogenetic and molecular genetic evolution of chronic myeloid leukemia
B Johansson et al.
ACTA HAEMATOLOGICA (2002)
BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance
A Slupianek et al.
MOLECULAR CELL (2001)